Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Now the shortages of Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound are over. The FDA determined in December and February, respectively, that the companies could meet demand.

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, ...

Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been ...

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Novo Nordisk’s arch-rival in the obesity market is Eli Lilly LLY. NVO’s Ozempic and Wegovy face strong competition from Lilly’s tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity).